Of note, signaling pathways related to inflammatory response such as TLRs and IL1β signaling pathways were linked to the imatinib insensitivity and pharmacological inhibition of IRAK1/4, mediators of inflammatory response signaling pathways, enhanced the efficacy on eliminating imatinib-insensitive CML LSCs. This evidence concerns the gene IRAK1 and chronic myelogenous leukemia, BCR-ABL1 positive.